VYGRVoyager Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $40M
- 50% YoY
- Operating margin
- -326.6%
- 214% YoY
- EBITDA
- −$128M
- 63% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired37% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $37M | $41M | $250M | $80M | $40M | 50% |
| Operating income | −$74M | −$51M | $122M | −$83M | −$132M | 58% |
| Net income | −$71M | −$46M | $132M | −$65M | −$120M | 84% |
| Operating cash flow | −$54M | −$13M | $78M | −$15M | −$132M | 765% |
| Capex | $2M | $2M | $3M | $4M | $3M | 26% |
| Stock-based comp | $11M | $9M | $11M | $15M | $15M | 0.0% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $2M | 64 | — |
| FY2024 | $3M | $891K | 93 | — |
| FY2023 | $3M | $5M | 138 | — |